Esophageal cancer
Conditions
Interventions
Group 1:Esophageal cancer resection of inflatable mediastinoscopy combined with laparoscopy
Group 2:Esophageal cancer resection of thoracoscopy combined with laparoscopy
Sponsors
West China Hospital, Sichuan University
Eligibility
Sex/Gender
All
Age
45 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Can understand the procedures and methods of this research, is willing to strictly follow the test plan to complete this test, and voluntarily sign the informed consent; 2. Aged 45-75 years; 3. Surgery patients with clinical diagnosis or pathological diagnosis of esophageal cancer who plan to undergo radical laparoscopic esophageal cancer surgery; 4. Have not undergone esophageal cancer surgery before; 5. The related toxicity before esophageal cancer surgery has recovered, and the level of organ function meets the following requirements: 1) Peripheral blood cell count: white blood cell count >= 3 x 10^9 / L and neutrophils >= 1.5 x 10^9 / L, blood platelet count >= 75 x 10^9 / L, hemoglobin >= 8 g / dL; 2) Liver function: total bilirubin <= 1.5 times the upper limit of normal reference value; AST and ALT <= 2.5 times the upper limit of normal reference value; in subjects with liver metastases, total bilirubin should be <= 2.5 times the upper limit of normal reference value, AST and ALT should be <= 5 times the upper limit of the normal reference value; 3) Renal function: serum creatinine <= 1.5 times the upper limit of normal reference value.
Exclusion criteria
Exclusion criteria: 1. History of hormone atomization or systemic hormone application within 1 month before admission; 2. Recent myocardial infarction, heart failure, neuromuscular diseases, etc .; 3. Other contraindications related to breathing training; 4. Bleeding during operation > 1000ml, transfer to open chest, etc .; 5. HIV infection or active hepatitis B or C; 6. Patients with coagulopathy; 7. Have a clear history of neurological or mental disorders, including epilepsy or dementia; 8. Researchers believe that patients may have other factors affecting the efficacy or safety evaluation of this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| DFS; | — |
Secondary
| Measure | Time frame |
|---|---|
| OS;quality of life;assessment of safety; | — |
Countries
China
Contacts
Public ContactYang Hu
West China Hospital, Sichuan University
Outcome results
None listed